Case Report
Year 2022,
Volume: 1 Issue: 1, 47 - 50, 01.01.2022
Abstract
Epilepsi sık karşılaşılan nörolojik hastalıklardan birisidir. Epilepsili kadınlarda gebelikte geçirilen nöbetler ve kullanılan anti-epileptik ilaçlar fetüsün sağlığını olumsuz yönde etkileyebilmektedir. Gebelikte kullanılan anti-epileptik ilaçların fetusta majör malformasyon sıklığını arttırdığı bilinmektedir. Antiepileptik ilaçların teratojen etkileri klinisyenin ilaç seçimini belirleyen en önemli kriterlerden birisidir. Karbamezepinin gebelikte kullanımının güvenli olduğu düşünülmekle birlikte az sayıda makalede karbamazepine bağlı fetusta majör malformasyonlar gelişebileceği bildirilmiştir.
Bu olgu sunumunda gebelik döneminde karbamazepin kullanan, takipsiz, epilepsili bir gebenin doğum sonrası izleminde büyük arter transpozisyonu tanısı alan bebeği sunulmuştur.
References
- Referans1. Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32:246-52.
- Referans2. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803-13.
- Referans3. Petersen I, Collings SL, McCrea RL, Nazareth I, Osborn DP, Cowen PJ, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clin Epidemiol. 2017;9:95-103.
- Referans4. Akar M, D. Dilli, Y. Yılmaz, O. Erdeve, S. Oguz, N. Uras, et al. A case of fetal carbamazepine syn-drome with right hemihypoplasia of the entire body. Genet Couns. 2012;23:19-24.
- Referans5. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epi-lepsy Res. 2008; 81:1–13.
- Referans6. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:133-41.
- Referans7.Kinney MO, Morrow J, Patterson CC, et al Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations J Neurol Neurosurg Psychiatry. 2018;89:1320-23.
- Referans8.Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:95.
- Referans9.Soydinc Ender H, Turgut A, Sak M, Ozler A, Evsen M S ,Basaranoğlu S, et al. Gebelik ve epilepsi: 46 olgunun retrospektif analizi ve perinatal sonuçlarının sağlıklı gebelerle karşılaştırılması. Perinatoloji Dergisi. 2013;21:12-16.
- Referans10.Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608-14.
- Referans11.Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010;341:c6581.
- Referans12.Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002;16:9-17.
- Referans13.Gupta G, Bansal A, Singh M. Antenatal carbamazepine use associated with d-TGA and ASD. Indian Pediatr. 2002;39:101-2.
- Referans14. Mısırlıoğlu ED, Aliefendioğlu D, Doğru MT, Sanli C, Oktay A. Transposition of the great arteries in a newborn whose mother was treated with carbamazepine during pregnancy. Anadolu Kardiyol Derg. 2007;7:344-5.
- Referans15. Cornelissen M, Steegers-Theunissen R, Kollée L, Eskes T, Motohara K, Monnens L. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol. 1993;168:884-8.
Year 2022,
Volume: 1 Issue: 1, 47 - 50, 01.01.2022
Abstract
References
- Referans1. Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32:246-52.
- Referans2. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803-13.
- Referans3. Petersen I, Collings SL, McCrea RL, Nazareth I, Osborn DP, Cowen PJ, et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clin Epidemiol. 2017;9:95-103.
- Referans4. Akar M, D. Dilli, Y. Yılmaz, O. Erdeve, S. Oguz, N. Uras, et al. A case of fetal carbamazepine syn-drome with right hemihypoplasia of the entire body. Genet Couns. 2012;23:19-24.
- Referans5. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epi-lepsy Res. 2008; 81:1–13.
- Referans6. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:133-41.
- Referans7.Kinney MO, Morrow J, Patterson CC, et al Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations J Neurol Neurosurg Psychiatry. 2018;89:1320-23.
- Referans8.Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:95.
- Referans9.Soydinc Ender H, Turgut A, Sak M, Ozler A, Evsen M S ,Basaranoğlu S, et al. Gebelik ve epilepsi: 46 olgunun retrospektif analizi ve perinatal sonuçlarının sağlıklı gebelerle karşılaştırılması. Perinatoloji Dergisi. 2013;21:12-16.
- Referans10.Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608-14.
- Referans11.Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010;341:c6581.
- Referans12.Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol. 2002;16:9-17.
- Referans13.Gupta G, Bansal A, Singh M. Antenatal carbamazepine use associated with d-TGA and ASD. Indian Pediatr. 2002;39:101-2.
- Referans14. Mısırlıoğlu ED, Aliefendioğlu D, Doğru MT, Sanli C, Oktay A. Transposition of the great arteries in a newborn whose mother was treated with carbamazepine during pregnancy. Anadolu Kardiyol Derg. 2007;7:344-5.
- Referans15. Cornelissen M, Steegers-Theunissen R, Kollée L, Eskes T, Motohara K, Monnens L. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol. 1993;168:884-8.
There are 15 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Case Report |
| Authors | |
| Early Pub Date | March 28, 2023 |
| Publication Date | January 1, 2022 |
| Published in Issue | Year 2022 Volume: 1 Issue: 1 |